The industry’s focus on living human beings and highly regulated standards provide unique considerations for business leaders. These attributes make the industry an ideal incubator for innovation. They have resulted in major breakthroughs the production of biofuels and agricultural yields and life-saving pharmaceuticals.
When it comes to strategies for generating revenue biotech start-ups have a myriad of options. The majority of them choose a technology partnership or an asset creation and out-licensing strategy. Technology partnering can generate more revenue and lower financial risk while out-licensing and asset creation strategy yields greater returns if it’s successful. A growing number of research-stage biotechs operate in a hybrid approach that combines both strategies.
Those who opt for the approach of developing based on products will be successful commercially when they are able to get their pipeline to the appropriate stage and find a pharmaceutical partner or investor with deep pockets. This can be a costly proposition however, and making sure that you balance opportunistic methods to leverage external resources with https://genotec-frankfurt.de/bio-pharmazeutika-werden-zu-einer-anerkannten-form-der-alternativmedizin/ scientific decisions about homegrown projects is vital.
The “platform” model is a second alternative to generate revenue. It is less costly than product-oriented research, but involves significant risk. In this model, a biotech owns and develops its platform technology before working with large pharma companies to develop a portfolio of drug discovery projects that specifically target diseases (i.e., disease x within biology y). This is the strategy Advinus Therapeutics and a few others have taken.